How should a patient with spontaneous bacterial peritonitis and a monobacterial ascitic fluid culture but a polymorphonuclear leukocyte count <250 cells/mm³ be managed?

Non-Neutrophilic Monobacterial SBP Management

Patients with a positive monobacterial ascitic fluid culture but PMN count <250 cells/mm³ should receive empirical antibiotic therapy if they have ANY signs or symptoms of infection (fever >37.8°C/100°F, abdominal pain, tenderness, encephalopathy, renal impairment, or unexplained hepatic decompensation), while awaiting culture results. 1

Clinical Decision Algorithm

Step 1: Assess for Infection Signs/Symptoms

If the patient has any of the following, treat empirically:

• Body temperature >37.8°C (100°F)
• Abdominal pain or tenderness
• Hepatic encephalopathy
• Renal impairment or rising creatinine
• Unexplained worsening of liver function
• Peripheral leukocytosis without other cause

If symptomatic: Start antibiotics immediately—do NOT wait for PMN count to rise 1, 2, 1

If asymptomatic: This represents monomicrobial non-neutrocytic bacterascites. Most cases (62%) resolve spontaneously without antibiotics. Perform repeat paracentesis to monitor for progression to SBP 2. However, prospective data show many symptomatic patients with PMN <250 cells/mm³ progress to SBP 1.

Step 2: Empirical Antibiotic Selection

First-line therapy (community-acquired):

• Cefotaxime 2g IV every 6-8 hours, OR
• Ceftriaxone 1g IV every 12-24 hours 1

Alternative for selected patients:

• Oral ofloxacin 400mg twice daily (only if no prior quinolone exposure, no vomiting, no shock, no grade II+ encephalopathy) 2, 3

Healthcare-associated/nosocomial infection:

• Broaden coverage empirically due to higher rates of gram-positive and multidrug-resistant organisms 4, 5

Step 3: Rule Out Secondary Peritonitis

This is critical because secondary peritonitis requires surgery and has 50-80% mortality if missed. Order additional ascitic fluid tests when PMN is elevated or clinical suspicion exists 1:

Red flags for secondary peritonitis:

• PMN count >1,000 cells/mm³
• Multiple organisms on Gram stain or culture
• Total protein ≥1 g/dL
• LDH > upper limit of normal for serum
• Glucose ≤50 mg/dL
• PMN count fails to drop after 48 hours of antibiotics
• CEA >5 ng/mL or alkaline phosphatase >240 U/L (suggests perforation)

If secondary peritonitis suspected: Obtain abdominal CT imaging immediately and add anaerobic coverage 1

Step 4: Add Albumin for High-Risk Patients

Administer IV albumin (1.5 g/kg at diagnosis, then 1 g/kg on day 3) if patient has:

• Creatinine ≥1.0 mg/dL (88 μmol/L), OR
• Blood urea nitrogen ≥30 mg/dL, OR
• Bilirubin ≥4-5 mg/dL (68 μmol/L)

This reduces progression to hepatorenal syndrome (from 30% to 10%) and mortality (from 29% to 10%) 3, 4. The benefit is less clear in patients without renal dysfunction or severe hepatic decompensation 3.

Step 5: Monitor Response

Repeat paracentesis at 48 hours if:

• Atypical presentation
• Atypical organisms
• Poor clinical response
• Concern for secondary peritonitis

Expected response: PMN count should decrease by >25% from baseline 4, 6. If not, broaden antibiotic coverage and investigate for secondary peritonitis.

Duration: 5-7 days of antibiotics (can discontinue once PMN <250 cells/mm³ if clinical improvement) 1, 4

Common Pitfalls to Avoid

1. Waiting for PMN count to rise before treating symptomatic patients—prospective data show symptomatic patients with PMN <250 cells/mm³ frequently progress to SBP 1

2. Missing secondary peritonitis—always maintain high suspicion and order additional ascitic fluid tests (protein, LDH, glucose) when infection is present 1

3. Using third-generation cephalosporins in nosocomial infections—these have higher rates of resistant organisms requiring broader coverage 4, 5

4. Failing to give albumin to high-risk patients—this is the only intervention proven to reduce mortality beyond antibiotics alone 3, 4

5. Treating asymptomatic bacterascites—most resolve spontaneously; repeat paracentesis instead 2, 4

Key Evidence Considerations

The most recent guidelines (2021 AASLD, 2018 KASL) consistently recommend treating symptomatic patients regardless of PMN count 1, 4. This represents evolution from older practice that strictly required PMN ≥250 cells/mm³. The rationale: infection can be detected at the bacterascites stage before neutrophil response occurs, and delaying treatment in symptomatic patients increases mortality risk 1, 2.

Culture positivity rates remain low (24-40% even with optimal technique) 6, 7, making clinical judgment paramount when cultures are positive but PMN counts are low.